Amgen Announces Webcast Of 2018 First Quarter Financial Results
THOUSAND OAKS, Calif., April 19, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2018 financial results on Tuesday, April 24, 2018, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.
Live audio of the conference call will be simultaneously broadcast over the internet and will be available to members of the news media, investors ...
Source: Amgen News Release - April 19, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Presents First-Of-Its-Kind Data At AAN Annual Meeting Reinforcing Robust And Consistent Efficacy Of Aimovig ™ (erenumab) For Migraine Patients With Multiple Treatment Failures
The LIBERTY Trial was Conducted in Patients who Have Tried Two to Four Therapies Without Success -- a Uniquely Difficult-to-Treat Population Often Excluded From Migraine Prevention Trials
Patients Taking Aimovig had Nearly Three-Fold Higher Odds of Having Their Migraine Days cut by Half or More Compared to Placebo
Safety and Tolerability Were Consistent With Results Seen in the Pivotal Clinical Program; Over 97 Percent of Those Taking Aimovig Completed the Double-Blind Treatment Phase
Data Selected by the American Academy of Neurology Science Committee as one of the Most Noteworthy Presentations at 2018 Annual Meetin...
Source: Amgen News Release - April 17, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Announces Rhode Island Will Be Location Of First US Next-Generation Biomanufacturing Plant
Revolutionary, Innovative Plant Offers Greater Flexibility, Speed and Efficiency
THOUSAND OAKS, Calif., April 10, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced plans to build a new state-of-the-art next-generation biomanufacturing plant at its campus in West Greenwich, R.I. The new plant, the first of its kind in the United States (U.S.), will employ Amgen's proven next-generation biomanufacturing capabilities and manufacture products for the U.S. and global markets.
A next-generation biomanufacturing plant incorporates multiple innovative technologies into a single facility, and therefore is built in h...
Source: Amgen News Release - April 10, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen To Present New Pre-Clinical Data Showcasing Robust Approach To Evaluating Potential Anti-Cancer Therapies At AACR 2018
First Data Presentations for CAR T Programs, Including DLL3 in Small Cell Lung Cancer and FLT3 in Acute Myeloid Leukemia
Pre-Clinical Data Evaluating Half-Life Extended Anti-BCMA BiTE® Presented for First-Time
New Data Include two Studies Investigating Mcl-1 Inhibitor AMG 176
THOUSAND OAKS, Calif., April 9, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new pre-clinical data for several of its novel investigational oncology candidates will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, April 14-18, 2018. Data spans Amgen's ear...
Source: Amgen News Release - April 9, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
European Commission Approves Expanded Indication For Amgen's XGEVA ® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
This Approval was Based on the Largest International Trial Ever Conducted for the Prevention of Skeletal-Related Events in Multiple Myeloma Patients
THOUSAND OAKS, Calif., April 2, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved an expanded indication for XGEVA® (denosumab) for the prevention of skeletal-related events in adults with advanced malignancies involving bone. The indication now covers patients with bone metastases from solid tumors and those with multiple myeloma. The approval is based on data from the Phase 3 '482 study, the largest international t...
Source: Amgen News Release - April 3, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
FDA Approves BLINCYTO ® (blinatumomab) To Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia In Adults And Children
BLINCYTO is the First-and-Only FDA-Approved Therapy for Minimal Residual Disease
Detection of Remaining Cancer Cells After Complete Remission is the Strongest Prognostic Factor for Relapse in Patients With Acute Lymphoblastic Leukemia
Accelerated Approval Based on Data From the Phase 2 BLAST Study, the Largest Prospective Trial in Minimal Residual Disease-Positive Acute Lymphoblastic Leukemia THOUSAND OAKS, Calif., March 29, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BLINCYTO® (blina...
Source: Amgen News Release - March 29, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Receives Positive CHMP Opinion Recognizing That Repatha ® (evolocumab) Prevents Heart Attacks And Strokes
Recommended Label Includes New Indication Based on the Repatha Cardiovascular Outcomes Study (FOURIER)
Amgen Continues to Work Closely With Payers on a Country-by-Country Basis to Ensure Access to Repatha for High-Risk Cardiovascular Patients
THOUSAND OAKS, Calif., March 23, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to include a new indication in the Repatha® (evolocumab) label for adults with established atherosclerotic cardiovascular disease (myocardial infarction, s...
Source: Amgen News Release - March 23, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen And Allergan Receive Positive CHMP Opinion For ABP 980 (Biosimilar Herceptin ®) For The Treatment Of Three Types Of Cancer
Recommended for Approval for the Same Indications as Herceptin® (Trastuzumab)
Positive Opinion for ABP 980 is Supported by Phase 3 Data in Patients With HER2-Postive Early Breast Cancer
THOUSAND OAKS, Calif., March 23, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the marketing authorization of ABP 980, a biosimilar to Herceptin® (trastuzumab). ABP 980 has been recommended for approval for the treatment of the same three types of cancer as...
Source: Amgen News Release - March 23, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
New Analyses Show Payer Utilization Management Criteria Deny Access To PCSK9 Inhibitors For Patients At The Highest Risk For Subsequent Cardiovascular Events
Research Presented at American College of Cardiology's 67th Annual Scientific Session Reveals More Than 110,000 Cardiovascular Events a Year Could Occur in High-Risk Patients With Cardiovascular Disease who are Rejected Access
Additional Study Calls for Assessment of Utilization Management Processes to Improve Access for Appropriate Patients and Prioritize Patients at the Highest Risk for Subsequent Cardiovascular Events
THOUSAND OAKS, Calif., March 9, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced data from two new studies exploring barriers to access for PCSK9 inhibitors and the potential consequence...
Source: Amgen News Release - March 9, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Announces Final Results Of Tender Offer
THOUSAND OAKS, Calif., March 8, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the final results of its modified Dutch auction tender offer, which expired at 12:00 Midnight, New York City time, at the end of Monday, March 5, 2018.
Amgen has accepted for purchase 52,083,333 shares of its common stock, $0.0001 par value per share, at a price of $192 per share, for an aggregate cost of approximately $10 billion, excluding fees and expenses relating to the tender offer. These shares represent approximately 7.2 percent of the shares outstanding. The tender offer was oversubscribed and pursuant to the terms of th...
Source: Amgen News Release - March 8, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Announces 2018 Second Quarter Dividend
THOUSAND OAKS, Calif., March 7, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.32 per share dividend for the second quarter of 2018. The dividend will be paid on June 8, 2018, to all stockholders of record as of the close of business on May 17, 2018.
About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand t...
Source: Amgen News Release - March 7, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen To Present At the Cowen and Company 38th Annual Health Care Conference
THOUSAND OAKS, Calif., March 7, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Cowen and Company 38th Annual Health Care Conference at 1:30 p.m. ET on Monday, March 12, 2018, in Boston. David W. Meline, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event.
About Amgen
Amgen is committed to unlocking the potential of biology for patients s...
Source: Amgen News Release - March 7, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Announces Preliminary Results Of Tender Offer
THOUSAND OAKS, Calif., March 6, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the preliminary results of its modified Dutch auction tender offer, which expired at 12:00 Midnight, New York City time, at the end of March 5, 2018.
Based on the preliminary count by American Stock Transfer & Trust Company, LLC, the depositary for the tender offer, a total of 54,297,698 shares of Amgen's common stock, $0.0001 par value per share, were properly tendered and not properly withdrawn at or below the purchase price of $192 per share, including 33,745,174 shares that were tendered by notice of guaranteed delivery. Amg...
Source: Amgen News Release - March 6, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Receives Positive CHMP Opinion For Delivery System Of Neulasta ® (pegfilgrastim)
Innovative Neulasta® Onpro® Kit is Designed to Provide the Right Dose for Patients at the Right Time
THOUSAND OAKS, Calif., Feb. 27, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending a label variation for Neulasta® (pegfilgrastim) to include the Neulasta® Onpro® Kit. The Neulasta Onpro Kit combines the efficacy of Neulasta with an innovative on-body injector (OBI) delivery system. Neulasta is indicated in the European Union (EU) for the reduction in the duration...
Source: Amgen News Release - February 27, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen To Present New Data From Repatha ® (evolocumab) Clinical Trials At ACC.18
Presentations Focus on Patients With Established Cardiovascular Disease and Include Data Exploring Consistency of LDL-C Reduction With Repatha
New Data Shows Patients at High Risk for Cardiovascular Events Continue to be Denied PCSK9 Inhibitors
THOUSAND OAKS, Calif., Feb. 26, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new data from the Repatha® (evolocumab) clinical trial program to be featured at the American College of Cardiology's 67th Annual Scientific Session (ACC.18) in Orlando, Fla., March 10-12, 2018. Presentations to include additional analyses from the Repatha cardiovascular outco...
Source: Amgen News Release - February 26, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
